Friday, February 01, 2019 11:49:24 AM
Earlier they had downgraded and lowered target price to $80.00
Sage Therapeutics stock price target raised to $90 from $80 at Leerink
Recent SAGE News
- Sage Therapeutics to Present at Upcoming March Investor Conferences • Business Wire • 02/28/2024 11:30:00 AM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 02/21/2024 09:35:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:02:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:02:15 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:09:44 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/14/2024 12:49:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/14/2024 12:20:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 11:45:53 AM
- Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress • Business Wire • 02/14/2024 11:30:00 AM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 01/31/2024 10:25:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:50:55 PM
- Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 • Business Wire • 01/31/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:10:55 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 01/23/2024 01:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:45:04 AM
- Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 01/08/2024 11:32:00 AM
- Sage Therapeutics Announces Changes to Board of Directors • Business Wire • 01/08/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:07:58 PM
- Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 • Business Wire • 01/02/2024 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/19/2023 01:32:56 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/19/2023 01:30:28 PM
- ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. • GlobeNewswire Inc. • 12/14/2023 11:30:00 AM
- ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. • Business Wire • 12/14/2023 11:30:00 AM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 12/08/2023 02:00:57 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/08/2023 01:30:50 PM
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM